Cargando…

Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma

The modest clinical benefits of neoadjuvant chemotherapy (NAT) in pancreatic ductal adenocarcinoma (PDAC) are associated with a lack of robust data on treatment‐induced changes in the tumor. To this end, comparative proteomic profiling of tumor tissue samples from treatment‐naïve (TN, n = 20) and NA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amrutkar, Manoj, Verbeke, Caroline S., Finstadsveen, Anette Vefferstad, Dorg, Linda, Labori, Knut Jørgen, Gladhaug, Ivar P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812839/ https://www.ncbi.nlm.nih.gov/pubmed/36400567 http://dx.doi.org/10.1002/1878-0261.13344

Ejemplares similares

Fatty acids abrogate the growth-suppressive effects induced by inhibition of cholesterol flux in pancreatic cancer cells
por: Li, Yuchuan, et al.
Publicado: (2023)

Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence
por: Sántha, Petra, et al.
Publicado: (2021)

Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing
por: Amrutkar, Manoj, et al.
Publicado: (2020)

Establishment and Characterization of Paired Primary Cultures of Human Pancreatic Cancer Cells and Stellate Cells Derived from the Same Tumor
por: Amrutkar, Manoj, et al.
Publicado: (2020)

Pancreatic stellate cell-induced gemcitabine resistance in pancreatic cancer is associated with LDHA- and MCT4-mediated enhanced glycolysis
por: Amrutkar, Manoj, et al.
Publicado: (2023)

Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells
por: Amrutkar, Manoj, et al.
Publicado: (2019)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer
por: Amrutkar, Manoj, et al.
Publicado: (2021)

Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer Cells
por: Lenggenhager, Daniela, et al.
Publicado: (2019)

Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives
por: Labori, Knut Jørgen
Publicado: (2022)

Surgical Treatment of Sporadic Pancreatic Neuroendocrine Tumors: A State of the Art Review
por: Haugvik, Sven-Petter, et al.
Publicado: (2012)

Prognostic Impact of Resection Margin Status in Distal Pancreatectomy for Ductal Adenocarcinoma
por: Sahakyan, Mushegh A., et al.
Publicado: (2021)

Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial
por: Labori, Knut Jørgen, et al.
Publicado: (2017)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2023)

ASO Author Reflections: Resection Margins in Distal Pancreatectomy for Ductal Adenocarcinoma—Does Surgery Tell the Whole Story?
por: Sahakyan, Mushegh A., et al.
Publicado: (2021)

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
por: Gartrell, Robyn D., et al.
Publicado: (2022)

Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective
por: Kurata, Yoshihiro, et al.
Publicado: (2021)

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma
por: Wysocka, Olga, et al.
Publicado: (2016)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
por: Kim, Hyung Sun, et al.
Publicado: (2021)

Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
por: Redegalli, M., et al.
Publicado: (2022)

Clarifying the role of adjuvant therapy after multi-agent neoadjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma
por: Lan, Xiaoyang, et al.
Publicado: (2023)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Profile of MMP and TIMP Expression in Human Pancreatic Stellate Cells: Regulation by IL-1α and TGFβ and Implications for Migration of Pancreatic Cancer Cells()
por: Tjomsland, Vegard, et al.
Publicado: (2016)

Risk factors and preventive strategies for post-operative pancreatic fistula after pancreatic surgery: a comprehensive review
por: Søreide, Kjetil, et al.
Publicado: (2016)

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
por: Hamad, Ahmad, et al.
Publicado: (2021)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma
por: Xie, Li, et al.
Publicado: (2019)

The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma
por: Kawahara, Kenji, et al.
Publicado: (2022)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives
por: Tiwari, Akash, et al.
Publicado: (2018)

Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis
por: Pomianowska, Ewa, et al.
Publicado: (2014)

Meta‐analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma
por: Schorn, S., et al.
Publicado: (2018)

Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma
por: Hartley, Christopher, et al.
Publicado: (2020)

Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research
por: Cloyd, Jordan M, et al.
Publicado: (2020)

Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma
por: Zhang, Yun, et al.
Publicado: (2021)

Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
por: Coppola, Alessandro, et al.
Publicado: (2023)

A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
por: Zhu, Lingyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r90i5fa3334nqt1mur81isa98a